Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.410 -0.350 (-4.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
What's Next: WAVE Life Sciences's Earnings Preview ↗
 
Via Benzinga
News headline image
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
1 Brand-New Big Reason to Buy This Biotech Stock Right Now ↗
This stock currently has a good balance of risk and potential rewards. 
Via The Motley Fool
News headline image
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. ↗
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
News headline image
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? ↗
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
News headline image
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases. 
Via MarketBeat
News headline image
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans ↗
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
News headline image
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere ↗
The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
Via Investor's Business Daily
News headline image
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE... 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics ↗
These two could become direct competitors relatively soon. 
Via The Motley Fool
News headline image
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Crude Oil Gains Over 1%; BioVie Shares Plunge ↗
 
Via Benzinga
News headline image
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views ↗
 
Via Benzinga
News headline image
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug ↗
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
Via Benzinga
News headline image
Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
Via MarketBeat
Topics Economy
News headline image
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.